IND226 also presented at the World Conference on Lung Cancer

The Canadian Cancer Trials Group Central Operations and Statistics Centre will be closed on Friday, April 19, 2019 for Good Friday. Regular business hours will resume on Monday, April 22 at 8:30 am EDT.
Thursday, December 15, 2016
Dr. Rosalyn Juergens, the study chair of IND.226, gave an oral presentation of the experience to date on IND.226, A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients with Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens at the 17th Annual World Conference on Lung Cancer in Vienna, Austria. She presented data of 24 patients with advanced non-small-cell lung cancer which found that, in this PD-1 unselected patient population, durvalumab 15mg/kg q3w and tremelimumab 1mg/kg (multiple doses q6w) or 3mg/kg (3 doses q6w) can be safely combined with full doses of platinum-doublet chemotherapy. Additional studies with this combination are being planned, including BR.34.

You can view the complete abstract presented by Dr. Juergens using this link


Dr. Rosalyn Juergens